Ceapro Inc. - President and CEO, Gilles Gagnon
President and CEO, Gilles Gagnon
Source: Ceapro Inc.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Ceapro Inc.’s (CZO) collaborative project with the University of Alberta has been accepted for publication to showcase its positive results
  • The article will discuss the results of Ceapro’s Pressurized Gas eXpanded (PGX) technology project
  • PGX is designed for processing challenging high-molecular-weight, water-soluble biopolymers (ex: proteins, starches, carbohydrates, etc.)
  • One biopolymer, sodium alginate (SA), proved to be the most promising candidate from the project
  • Ceapro Inc. (CZO) is up 2.98 per cent trading at $0.69 per share as of 1:49 p.m. ET

Ceapro’s (CZO) collaborative project with the University of Alberta has been accepted for publication to showcase its positive results.

The company’s project is based on its Pressurized Gas eXpanded (PGX) technology, which allegedly has advantages over conventional drying and purification technologies. It can be used to process biopolymers into high-value, fine-structured, open porous polymer structures and novel bio-composites.

PGX is designed to be suited for processing challenging high-molecular-weight, water-soluble biopolymers (ex: proteins, starches, carbohydrates, etc.). It can make ultra-light, highly porous polymer structures continuously, which Ceapro stated is impossible using existing technologies.

The company stated the project was completed last year in April, and most PGX-processed biopolymers, sodium alginate (SA), an extract from brown algae, were retained as the most promising candidate to be included in Ceapro’s portfolio.

The company shared the results are from work done to investigate the effect of PGX processing parameters and scale-up on the physicochemical properties of PGX-SA as a stand-alone novel bio aerogel. However, results demonstrate that PGX-SA can be similar and more easily loaded with a higher amount of coenzyme Q10 (CoQ10).

“While PGX-processed alginate is poised to become a key commercial strategic asset for the company along with beta-glucan from yeast, findings of this study could lead to the development of many other more potent delivery systems enabling Ceapro to expand into a high-end Life Science company,” Gilles Gagnon, President and CEO of Ceapro, said.

Ceapro Inc. is a Canadian biotechnology company developing extraction technology using materials from oats and other renewable resources. Its technology can support cosmeceutical, nutraceutical, and therapeutic products for humans and animals.

Ceapro Inc. (CZO) is up 2.98 per cent trading at $0.69 per share as of 1:49 p.m. ET.


More From The Market Herald

" RevoluGROUP (TSXV:REVO) signs business development strategy

RevoluGROUP (REVO) has signed a business development agreement for a future joint strategy.

" Diagnos (TSXV:ADK) closes non-brokered private placement

Diagnos (ADK) has closed its non-brokered private placement for gross proceeds of $500,000.

" OOOOO Entertainment (TSXV:OOOO) partner signs referral agreement with NFT marketplace

OOOOO Entertainment (OOOO) partner, Shiller, has signed a referral agreement with Rarible.

" Gamelancer Media (CSE:GMNG) closes non-brokered private placement

Gamelancer Media Corp. (GMNG) has closed the final tranche of its non-brokered private placement for gross proceeds of $439,000.